Trial of topical British Anti-Lewisite (BAL) to prevent cyclophosphamide induced alopeciae

Submission date	Recruitment status	Prospectively registered
01/07/2001	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
01/07/2001	Completed	Results
Last Edited	Condition category	[] Individual participant data
26/02/2015	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)Scientific

Contact name

- - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
BAL

Study information

Scientific Title

Trial of topical British Anti-Lewisite (BAL) to prevent cyclophosphamide induced alopeciae

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Lung (non-small cell) cancer

Interventions

- 1. BAL Group: Chemotherapy, single-agent cyclophosphamide plus topical application of BAL. BAL lotion to be applied to posterior half of the scalp including occipital parietal areas two hours before and within 15 minutes of completing cyclophosphamide infusion. BAL to be left on the scalp for two to three hours.
- 2. Control Group: Chemotherapy, single-agent cyclophosphamide.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

British Anti-Lewisite, cyclophosphamide

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2000

Completion date

31/12/2003

Eligibility

Key inclusion criteria

- 1. Lung cancer patients due to receive single-agent cyclophosphamide
- 2. Hair to be cut as short as possible before application of BAL

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit

London United Kingdom NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

LocationUnited Kingdom

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration